Tiaa Fsb bought a new position in shares of Allergan PLC. (NYSE:AGN) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 47,676 shares of the company’s stock, valued at approximately $11,590,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Veritas Asset Management LLP acquired a new position in Allergan PLC. in the first quarter valued at about $761,339,000. Iridian Asset Management LLC CT lifted its position in Allergan PLC. by 141.3% during the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after purchasing an additional 751,848 shares during the period. Renaissance Technologies LLC acquired a new stake in Allergan PLC. during the first quarter worth about $124,255,000. Vanguard Group Inc. grew its stake in Allergan PLC. by 2.2% during the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after buying an additional 482,220 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. grew its stake in Allergan PLC. by 24.1% during the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares in the last quarter. 82.03% of the stock is currently owned by institutional investors.

AGN has been the topic of several recent analyst reports. Wells Fargo & Company reissued a “buy” rating on shares of Allergan PLC. in a report on Monday. Barclays PLC restated an “equal weight” rating on shares of Allergan PLC. in a research report on Monday. UBS AG reaffirmed a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Tuesday, September 26th. Credit Suisse Group reaffirmed an “outperform” rating and set a $266.00 price target (down previously from $286.00) on shares of Allergan PLC. in a report on Tuesday, September 26th. Finally, Mizuho reiterated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Monday, September 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $271.84.

Shares of Allergan PLC. (NYSE AGN) opened at 209.80 on Wednesday. The firm has a market capitalization of $70.14 billion, a P/E ratio of 6.39 and a beta of 1.15. The company has a 50-day moving average price of $220.20 and a 200-day moving average price of $233.72. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the business earned $3.35 earnings per share. The business’s quarterly revenue was up 8.8% on a year-over-year basis. Equities analysts predict that Allergan PLC. will post $16.22 EPS for the current year.

Allergan PLC. declared that its board has approved a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.33%. Allergan PLC.’s payout ratio is 9.95%.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.